It is administered by a single dose intratumorally (450 μg), subcutaneously (50 mg/kg), and orally (60 mg/kg), leading to the stimulation of IFN-β secretion within tumors, tumor regression, and the development of long-lasting antitumor immunity. This evidence concerns the gene IFNB1 and neoplasm.